Aerie Pharmaceuticals Inc
NASDAQ:AERI
Aerie Pharmaceuticals Inc
Net Income (Common)
Aerie Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Aerie Pharmaceuticals Inc
NASDAQ:AERI
|
Net Income (Common)
-$36.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$40.6B
|
CAGR 3-Years
39%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$2.1B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-21%
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$5.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
See Also
What is Aerie Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-36.6m
USD
Based on the financial report for Sep 30, 2022, Aerie Pharmaceuticals Inc's Net Income (Common) amounts to -36.6m USD.
What is Aerie Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
21%
Over the last year, the Net Income (Common) growth was 78%. The average annual Net Income (Common) growth rates for Aerie Pharmaceuticals Inc have been 43% over the past three years , 21% over the past five years .